Rectal carcinoma
MONDO:0044937A malignant epithelial neoplasm that arises from the rectum and invades through the muscularis mucosa into the submucosa. The vast majority are adenocarcinomas.
Also known as: cancer of rectum, cancer of the rectum, rectal cancer, carcinoma of rectum, carcinoma of the rectum, rectal carcinoma, rectum carcinoma
3269 clinical trials for this condition and its sub-types, 54 tagged with Rectal carcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Rectal carcinoma
-
Rectum adenocarcinoma 232 trials · 233 incl. sub-types
4 sub-types
- Anus adenocarcinoma 0 trials · 1 incl. sub-types Sub-types →
- Rectal signet ring cell adenocarcinoma 1 trial
- Rectum mucinous adenocarcinoma 1 trial Sub-types →
- Rectal medullary carcinoma 0 trials
-
Anal carcinoma 85 trials · 129 incl. sub-types
4 sub-types
- Anal squamous cell carcinoma 40 trials · 49 incl. sub-types Sub-types →
- Anal canal carcinoma 4 trials · 34 incl. sub-types Sub-types →
- Anal margin carcinoma 1 trial · 6 incl. sub-types Sub-types →
- Anus adenocarcinoma 0 trials · 1 incl. sub-types Sub-types →
-
Squamous cell carcinoma of rectum 8 trials · 53 incl. sub-types
3 sub-types
- Anal squamous cell carcinoma 40 trials · 49 incl. sub-types Sub-types →
- Rectal adenosquamous carcinoma 0 trials
- Rectal cloacogenic carcinoma 0 trials
-
Rectum carcinoma in situ 1 trial · 13 incl. sub-types
1 sub-type
- Anal canal carcinoma in situ 12 trials
-
Rectosigmoid carcinoma 5 trials
-
Rectal sarcomatoid carcinoma 0 trials
Most studied deeper sub-types
-
Can a 16-Hour fast supercharge immunotherapy against rectal cancer?
Disease control Not yet recruitingThis phase II trial is testing whether a 16-hour fast before each dose of the immunotherapy drug serplulimab, combined with chemotherapy, can improve outcomes for people with a common type of locally advanced rectal cancer. The approach aims to boost the immune system's ability t…
Phase 2 • Sponsor: Zhejiang University • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New adaptive radiation boosts rectal cancer response rates
Disease control Not yet recruitingThis study tests a personalized radiation approach for locally advanced rectal cancer. By adjusting the radiation dose halfway through treatment based on a special MRI scan, doctors hope to increase the number of patients whose tumors completely disappear before surgery. The tria…
Sponsor: IRCCS San Raffaele • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Triple chemo may help rectal cancer patients avoid surgery
Disease control Not yet recruitingThis Phase 3 trial tests whether a three-drug chemotherapy combination (FOLFOXIRI) works better than the standard two-drug combination (CAPOX/FOLFOX) for people with high-risk locally advanced rectal cancer. Both groups also receive chemoradiation, and then either surgery or a wa…
Phase 3 • Sponsor: J. W. A. Burger • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Blood test could revolutionize rectal cancer monitoring
Knowledge-focused Not yet recruitingThis study looks at whether a blood test that finds tiny bits of tumor DNA (ctDNA) can help doctors monitor rectal cancer more closely than standard scans. Researchers will collect blood and tissue samples from 60 adults with non-spreading rectal cancer before and after standard …
Sponsor: Massachusetts General Hospital • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
New study looks back at rectal cancer treatments to find what works best
Knowledge-focused Not yet recruitingThis study will review medical records of 100 adults with locally advanced rectal cancer treated between 2018 and 2025 at hospitals in Egypt. Researchers will look at which treatments patients received and how they fared, including survival and side effects. The goal is to unders…
Sponsor: Sohag University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:13 UTC